# US 2022/0276262 A1 · Methods and Products for Assessing Lysosomal System Flux

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0276262 A1
- Document ID: US20220276262A1
- Status: Published application
- Kind: A1
- Application number: 17/637,494
- Filed: 2020-08-28
- Published: 2022-09-01
- Earliest claimed: 2019-08-30
- Assignees: South Australian Health and Medical Research Institute Limited
- Applicants: South Australian Health and Medical Research Institute Limited
- Inventors: Timothy John Sargeant; Julien Michel Bensalem
- Web page: https://patentgrep.com/patent/US20220276262A1

## CPC

- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 1/34: Purifying; Cleaning {(processes or apparatus for extracting or separating nucleic acids from biological samples C12N15/1003)}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 2500/10: involving cells
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to relates to methods and products for assessing lysosomal system flux. In addition, the present disclosure also provides systems for assessing lysosomal system flux, and methods of identifying markers indicative of lysosomal system flux. In certain embodiments, the present disclosure provides a method of assessing lysosomal system flux in a subject. The method comprises determining the level of a lysosomal system marker in a sample of whole blood from the subject, the level of the lysosomal system marker being determined based on the level of the marker following treatment of the whole blood with an inhibitor of lysosomal system function.

## Claims

### Claim 1

A method of assessing lysosomal system flux in a subject, the method comprising determining the level of a lysosomal system marker in a sample of whole blood from the subject, the level of the lysosomal system marker being determined based on the level of the marker following treatment of the whole blood with an inhibitor of lysosomal system function.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the inhibitor of lysosomal system function comprises one or more of chloroquine, bafilomycin A1, E-64d, leupeptin, and pepstatin A.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the method comprises determining the level of the lysosomal system marker in one or more of peripheral blood mononuclear cells, polymorphonuclear cells, and other cellular populations, derived from the whole blood treated with the inhibitor of lysosomal system function.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the lysosomal system marker comprises an LC3 and/or a GABARAP/GATE-16 protein and/or an LC3 interacting cargo adaptor protein.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the lysosomal system marker comprises a LC3B protein.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the lysosomal system marker comprises LC3B-II protein or a P62 protein.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the method comprises comparison of the level of the lysosomal system marker with the level of a marker in whole blood without treatment with an inhibitor of lysosomal system function.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the method comprises determining the level of the lysosomal system marker using immunological detection.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the immunological detection comprises ELISA or immunocytochemical staining.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the immunological detection comprises Western blotting.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the method comprises:
obtaining a sample of whole blood from the subject;
treating the sample of whole blood with the inhibitor of lysosomal system function; and
determining the level of the lysosomal system marker in the whole blood so treated as compared to the level of the lysosomal system marker in whole blood without treatment.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

A kit for assessing lysosomal system flux in whole blood using the method according to claim 1, the kit comprising the following components:
a reagent for detecting the lysosomal system marker; and
optionally one or more of an inhibitor of lysosomal system function, an anti-coagulant,
a biochemical extract reagent and a cell lysis reagent.

### Claim 14

A system for assessing lysosomal system flux in a subject, the system comprising:
a processor for receiving data indicative of the level of a lysosomal system marker in whole blood treated with an inhibitor of lysosomal system function; and
a memory with software resident in the memory, and accessible to the processor, wherein the software comprises a series of instructions executable by the processor to convert the data to a measurement of lysosomal system flux in the subject.

### Claim 15 (depends on 14)

The system according to claim 14, wherein the system further comprises a device for determining the level of a lysosomal system marker in a sample of cells and/or lysed cells derived from a whole blood treated with an inhibitor of lysosomal system function.

### Claim 16 (depends on 1)

A method of treating a subject suffering from, or susceptible to, a disease, condition or state associated with autophagic dysfunction, the method comprising determining the lysosomal system flux in the subject by a method according to claim 1, and treating the subject on the basis of the level of lysosomal system flux determined.

### Claim 17

A method of identifying a marker present in blood indicative of lysosomal system flux in a subject, the method comprising:
determining the level of a candidate marker indicative of lysosomal system flux in whole blood treated with an inhibitor of lysosomal system function; and
identifying the candidate marker as a marker indicative of lysosomal system flux.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the marker present in blood is a plasma and/or serum marker.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the marker is indicative of lysosomal system flux in the absence of treatment of whole blood with an inhibitor of lysosomal system function.

### Claim 20 (depends on 17)

The method according to claim 17, wherein the method comprises computational analysis and/or machine learning to identify the candidate marker as a marker indicative of lysosomal system flux.
